Alkermes/ALKS

$24.42

-2.28%
-
1D1W1MYTD1YMAX

About Alkermes

Alkermes plc is a global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.

Ticker

ALKS

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Richard Pops

Employees

2,100

Headquarters

Dublin, Ireland

Alkermes Metrics

BasicAdvanced
$4.08B
Market cap
11.82
P/E ratio
$2.07
EPS
0.57
Beta
-
Dividend rate
$4.08B
0.57194
$33.71
$22.01
1.91M
2.856
2.497
23.924
24.173
6.588
25.32%
46.22%
33.69%
11.819
2.453
3.39
3.65
11.548
49.61%
1,574.8%
16.99%

What the Analysts think about Alkermes

Analyst Ratings

Majority rating from 13 analysts.
Buy

Price Targets

Average projection from 11 analysts.
47.05% upside
High $50.00
Low $25.00
$24.42
Current price
$35.91
Average price target

Alkermes Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
29.86% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$377.4M
-0.92%
Net income
$112.7M
136.27%
Profit margin
29.86%
138.5%

Alkermes Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 57.15%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
$0.01
$0.55
$0.64
$0.22
-
Expected
-$0.01
$0.46
$0.44
$0.51
$0.67
Surprise
-174.07%
19.05%
44.7%
-57.15%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Alkermes stock?

Alkermes (ALKS) has a market cap of $4.08B as of April 14, 2024.

What is the P/E ratio for Alkermes stock?

The price to earnings (P/E) ratio for Alkermes (ALKS) stock is 11.82 as of April 14, 2024.

Does Alkermes stock pay dividends?

No, Alkermes (ALKS) stock does not pay dividends to its shareholders as of April 14, 2024.

When is the next Alkermes dividend payment date?

Alkermes (ALKS) stock does not pay dividends to its shareholders.

What is the beta indicator for Alkermes?

Alkermes (ALKS) has a beta rating of 0.57. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Alkermes stock price target?

The target price for Alkermes (ALKS) stock is $35.91, which is 47.05% above the current price of $24.42. This is an average based on projections from 11 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Alkermes stock

Buy or sell Alkermes stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing